Allergan drops $958M on migraine drug maker MAP Pharma January 23, 2013 By MassDevice staff Aesthetics giant Allergan (NYSE:AGN) agreed to a nearly $1 billion acquisition of MAP Pharmaceuticals (NSDQ:MAPP), maker of an experimental migraine drug therapy called Levadex.